MSC 2364447

Drug Profile

MSC 2364447

Alternative Names: M-2951; MSC2364447; MSC2364447C

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Merck Serono
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders; Systemic lupus erythematosus
  • Phase Unknown Multiple sclerosis

Most Recent Events

  • 29 Nov 2016 EMD Serono Research & Development Institute and Merck plan a phase II trial for Multiple sclerosis in USA and Germany (PO) (NCT02975349)
  • 23 Nov 2016 Investigation in Multiple sclerosis in USA (PO) before November 2016
  • 23 Nov 2016 EMD Serono Research & Development Institute and Merck plan a phase II trial for Systemic lupus erythematosus in USA, Argentina, Brazil, Bulgaria, Chile, Colombia, Germany, Italy, South Korea, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russia, South Africa and Taiwan (PO) (NCT02975336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top